Mehmet Ozkaynak, MD
Pediatric Hematology-Oncology · Hawthorne, NYNPI 1720088453
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Novartis at 47.1% of the total. Reporting peaked in 2023 at $452 and has fallen 52.9% since, to $213 in 2025.
Across 79 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$900
- AstraZeneca$211
- CSL Behring$140
- Amgen$76
- Bio Products Laboratory USA, Inc.$58
- HEMA Biologics, LLC$53
- plus $474 from 18 others
What the payments were for
- Speaking & faculty fees$1508%
- Food & beverage$1,76392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 39 | $900 |
| AstraZeneca(2 entities) | 4 | $211 |
| CSL Behring | 6 | $140 |
| Amgen | 3 | $76 |
| Bio Products Laboratory USA, Inc. | 3 | $58 |
| HEMA Biologics, LLC | 2 | $53 |
| Pfizer | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Sobi, Inc | 2 | $34 |
| AVEO Pharmaceuticals, Inc. | 1 | $32 |
| Agios Pharmaceuticals, Inc. | 1 | $31 |
| USWM, LLC | 1 | $31 |
| Grifols USA, LLC | 1 | $30 |
| Genentech USA, Inc. | 1 | $24 |
| Biocon Biologics Inc | 1 | $23 |
| Bayer | 1 | $21 |
| Octapharma USA, Inc. | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $20 |
| Emmaus Medical, Inc. | 1 | $20 |
| Springworks Therapeutics, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Dova Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$150
How this compares
$1,913 in reported general payments places this provider in the 65th percentile of 196 pediatric hematology-oncology providers in New York.
See all pediatric hematology-oncology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pediatric hematology-oncology in Hawthorne
- Mitchell CairoHawthorne$1.1M
- Claudio SandovalHawthorne$54K
- Oya TugalHawthorne$49K
- Sujit ShethNew York$359K
- Jaap Jan BoelensNew York$303K
- Mary SugrueGarden City$253K
- James BusselNew York$204K
- Saara KavianyNew York$144K
- Gary BrittenhamNew York$137K
- Jennifer DavilaBronx$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.